Does dexrazoxane provide a long-term cardioprotective effect in young adult-aged survivors of childhood cancer exposed to anthracyclines?
Dexrazoxane is associated with long-term cardioprotection in childhood cancer survivors nearly 20 years after anthracycline exposure.
Among young adult-aged survivors of childhood cancer, dexrazoxane was associated with a cardioprotective effect nearly 20 years after initial anthracycline exposure.
Chow et al. (2023) studied this question.